Brian Daniel Webster, an officer and director at Kestra Medical Technologies, has filed to sell 15,000 shares of common stock. This sale, valued at approximately $443,389, is part of a performance stock issuance. The transaction is significant as it showcases the executive's ongoing involvement in the company's equity management.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc. operates in the surgical and medical instruments industry. The company is based in Kirkland, Washington, and has been active in the market, focusing on innovative medical solutions. The recent filing is part of a series of transactions involving Webster, who has been regularly trading shares since mid-2026.
What the Filing Says
The filing, dated October 20, 2026, indicates that the shares are being sold under the 1933 Act. It specifies that the shares were acquired as part of an equity compensation plan, with the acquisition date listed as July 14, 2026. The filing states, "The nature of acquisition transaction is Performance Stock Issuance." This aligns with common practices in executive compensation.
Impact
This transaction may affect shareholders and potential investors in Kestra Medical Technologies. As an officer and director, Webster's actions can influence market perception, particularly in the surgical and medical instruments sector. The filing does not mention any specific competitors, but the industry is known for its competitive nature.
What's Next
The filing does not say what happens next regarding the proceeds from this sale or any future plans for additional stock transactions by Webster.